WilmerHale Represents PTC Therapeutics in $1.5B Evrysdi® Royalty Agreement with Royalty Pharma

WilmerHale Represents PTC Therapeutics in $1.5B Evrysdi® Royalty Agreement with Royalty Pharma

Client News

Related Solutions

We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
On October 19, 2023, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced an agreement with Royalty Pharma plc. to monetize PTC’s remaining interests in its Evrysdi royalty stream for up to $1.5 billion. Under the agreement, Royalty Pharma acquired certain royalties on Evrysdi for $1.0 billion upfront. The agreement also includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to an additional $500 million, and for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date. PTC maintains all economics associated with up to $250 million in remaining commercial sales milestones associated with Evrysdi global net sales.

The agreement builds on the previous strategic partnership established in 2020 with Royalty Pharma.

The WilmerHale legal team advising PTC Therapeutics was led by George Shuster and Nathan Moore with assistance from Emily Powers.
 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel